Although therapeutic combinations will be required to improve outcomes in #GIST, this phase Ib study from @sloan_kettering combining FGFR inhibitor BGJ398 + #imatinib in refractory #GIST reminds us to keep working hard! https://t.co/Hp33Wz6p04
RT @RapidScience: Phase Ib study of BGJ398, pan-FGFR #kinaseinhibitor w/ #imatinib in #GIST patients Ciara M. Kelly Samuel Singer Cristina…
Phase Ib study of BGJ398, pan-FGFR #kinaseinhibitor w/ #imatinib in #GIST patients Ciara M. Kelly Samuel Singer Cristina R. Antonescu @alexshoushtari @sandrapdangelo @WTapMD @WeillCornell @sloan_kettering Investigational New Drugs #sarcoma @ClinMedJournals